Peptide Ltd. is a leading biotechnology company and owns exclusive international rights to market a number of neurological drugs developed from unique peptides. It also owns a portfolio of patents and most significantly the "Peptide Technology" that has been patented (US Patent #5,989,857) therefore permitting the development of hundreds of novel therapeutic proteins for which we have exclusive intellectual property, research, manufacturing, marketing and distribution rights and our aim is:

"To improve the QUALITY OF LIFE for patients afflicted with disabling or terminal diseases."

We fulfil this mission by supporting research that results in improved therapies. This is achieved by ensuring caring support and continuation of patient studies.

Our work began in 1986 to explore new methods for the detection and monitoring of such diseases. Recently we have expanded our charter to include studying all aspects of disease from diagnosis and treatment through to cure.

CURRENT STATUS:

The organisation is targeting several diseases that have evaded successful treatment to date. Diseases that have a devastating impact on the quality of life of both patients and caretakers/carers. Therefore, our goal is to help the millions of people whose lives have been impacted by such diseases.

Our various peptide technologies and areas of interest include:

• Neurological disorders, disease and ailments using patented Neuropeptides conducted by Esperanza Peptide, with our primary focus on Multiple Sclerosis (MS), also disorders and diseases such as Primary Lateral Sclerosis (PLS) Muscular Dystrophy (MD), Motor Neuron Disease-ALS (MND-ALS), Autism, Post Stroke, Adrenomyeloneuropathy (AMN), Ataxias, Olivopontocerebellaratrophy (OPCA), Lyme Disease and Leukodystophies.
• Neoplasms with emphasis on Mammary, Melanoma and Prostate Cancer.
• Infectious diseases such as Hepatitis, Polio, Herpes and HIV / AIDS.

THE NEED FOR OUR TREATMENTS REACHES AROUND THE GLOBE:

Far too many people that have been diagnosed with disabling diseases find themselves without medical insurance to pay for the medications that they so desperately require. In most instances the annual cost of treatments exceeds $30,000. Such a financial burden adds further stress upon entire families.

There are many crippling and fatal diseases globally that are threatening to overwhelm the countries involved. Many third world countries have meagre resources to support efforts at finding a solution to their healthcare crisis. Appropriate medications and vaccines are usually beyond their finances and as such, further exacerbating the very difficult challenge such countries face.

The only solution is to introduce cost-effective options. The development of agents which will help detect, monitor and treat some of the world's most common ailments is the driving force behind Esperanza Peptide. Improving the quality of life for millions of people worldwide is our ultimate goal.